Why Hims & Hers Health Stock Just Crashed

Hims & Hers missed Q1 expectations badly, reporting a loss of $0.40 per share versus $0.01 expected and revenue of $608 million versus $616.5 million consensus. Sales grew just 4% despite 9% subscriber growth, but management raised full-year revenue guidance to $2.8 billion-$3.0 billion and said free cash flow was positive at $53 million in the quarter. The stock fell 12% on the miss, though the guidance raise partially offsets the weak quarter.

Analysis

The market is treating this as a simple miss, but the more important signal is that top-line deceleration is happening even while customer count grows. That usually means either weaker monetization per user or a mix shift toward lower-ticket offerings, which is more damaging to the durability of the growth narrative than a single EPS miss. The guidance raise softens the headline, but it also implies management is leaning harder on volume and product expansion to offset a less efficient revenue engine.

The second-order issue is legal and platform risk: the company is pivoting away from the highest-risk category into branded resale, which reduces litigation exposure but also compresses margin structure and bargaining power. That makes future growth more dependent on operational execution, cross-sell, and acquisition efficiency rather than category arbitrage. In other words, the business may become safer but less profitable than bulls are underwriting.

The stock can bounce if investors decide the free-cash-flow inflection matters more than GAAP losses, especially in a risk-on tape where cash generation gets rewarded over accounting earnings. But the setup is vulnerable over the next 1-3 quarters if revenue per subscriber keeps sliding or if the market concludes the forward guide is being pulled forward from a weaker starting base. The key question is whether this is a temporary mix shift or the first evidence that the growth model is saturating.

Competitively, the likely winners are branded GLP-1 suppliers and any healthcare platform with stronger payer integration or better economics per script. HIMS still has a brand and distribution advantage, but the gap narrows if it can no longer monetize the most buzzy category on its own terms. That increases the odds of multiple compression versus other consumer-health growth names if investors stop believing in a premium growth/quality hybrid story.

Key Decisions for Investors

• Short HIMS on strength for a 1-3 month trade if the stock retraces part of the post-earnings drop; use a tight stop above the pre-earnings level because the near-term bounce risk is real, but the reward is a further de-rating if next quarter confirms lower monetization per subscriber.
• Pair trade: long LLY / short HIMS over the next 3-6 months. If HIMS is forced further into branded resale, Lilly captures more of the economics while HIMS loses differentiation; the pair reduces broad healthcare beta and isolates channel-structure risk.
• Consider buying HIMS put spreads 1-2 quarters out rather than outright puts. The implied move after a large gap-down should make defined-risk downside structures more efficient if revenue-per-user weakness persists, while capping theta bleed if management delivers a relief rally.
• For event-driven investors, wait for the next quarter before adding exposure. The bull case needs proof that guidance is being driven by sustainable monetization, not just more users and category mix; absent that, upside is likely capped by multiple compression.
• Avoid chasing the implied FCF story until two consecutive quarters show operating leverage. The current setup is attractive for a tactical long only if the market starts pricing HIMS as a cash generator; otherwise, the risk/reward skews toward lower multiples rather than earnings power expansion.